Copyright
©The Author(s) 2022.
World J Gastroenterol. Sep 14, 2022; 28(34): 5058-5075
Published online Sep 14, 2022. doi: 10.3748/wjg.v28.i34.5058
Published online Sep 14, 2022. doi: 10.3748/wjg.v28.i34.5058
Characteristics | N | n (%) or mean ± SD | |
Age | 94 | 42.5 (15.3) | |
Gender | Male | 94 | 56 (59.6) |
BMI (kg/m2) | 91 | 25.4 (4.5) | |
Race | American Indian/Alaska Native | 94 | 1 (1.1) |
Asian | 5 (5.3) | ||
White | 88 (93.6) | ||
Employment status | Disability | 2 (2.1) | |
Employed (fulltime, part time < 35 h/week) | 63 (67.0) | ||
Homemaker | 3 (3.2) | ||
Retired | 12 (12.8) | ||
Student | 6 (6.4) | ||
Temporary leave of absence | 1 (1.1) | ||
Unemployed | 6 (6.4) | ||
Unknown | 1 (1.1) | ||
Tobacco use | Current smoker | 94 | 2 (2.1) |
Former smoker | 34 (36.2) | ||
Never smoked | 55 (58.5) | ||
Unknown | 3 (3.2) | ||
Alcohol use | Non-drinker | 94 | 20 (21.3) |
Ex-drinker | 5 (5.3) | ||
Light (less than 2 drinks per day) | 61 (64.9) | ||
Moderate (2-4 drinks per day) | 5 (5.3) | ||
Unknown | 3 (3.2) | ||
Age at UC diagnosis (yr) | 98 | 34.5 (15.3) | |
Disease duration (yr) | 98 | 7.9 (8.0) | |
Family history of UC | No | 98 | 59 (60.2) |
Yes | 20 (20.4) | ||
Unknown | 19 (19.4) | ||
Montreal classification of extent of UC | E2 | 97 | 55 (56.7) |
(prior 3 mo) | E3 | 42 (43.3) | |
Mayo Endoscopic Subscore | 1 | 90 | 1 (1.1) |
(prior 3 mo) | 2 | 66 (73.3) | |
3 | 23 (25.6) | ||
Endoscopy (prior 6 mo) | Yes | 98 | 91 (92.9) |
UC-related ED visit (prior 6 mo) | Yes | 98 | 13 (13.3) |
UC-related hospitalization (prior 6 mo) | Yes | 98 | 12 (12.2) |
Previous biologic use | Yes | 44 | 5 (11.4) |
Medication use: | Corticosteroids | 98 | 63 (64.3) |
Since UC diagnosis to prior 6 mo | Imuran (azathioprine) | 37 (37.8) | |
6-MP | 8 (8.2) | ||
5-ASA | 83 (84.7) | ||
Methotrexate | 5 (5.1) | ||
Cyclosporine | 1 (1.0) | ||
Medication use: | Corticosteroids | 98 | 61 (62.2) |
Since prior 6 mo to current | Imuran (azathioprine) | 39 (39.8) | |
6-MP | 5 (5.1) | ||
5-ASA | 67 (68.4) | ||
Methotrexate | 8 (8.2) | ||
Cyclosporine | 0 (0.0) |
- Citation: Bessissow T, Nguyen GC, Tarabain O, Peyrin-Biroulet L, Foucault N, McHugh K, Ruel J. Impact of adalimumab on disease burden in moderate-to-severe ulcerative colitis patients: The one-year, real-world UCanADA study. World J Gastroenterol 2022; 28(34): 5058-5075
- URL: https://www.wjgnet.com/1007-9327/full/v28/i34/5058.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i34.5058